A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer.

Trial Profile

A Phase II, Randomized, Controlled, Open-Label Study Comparing Standard Chemoradiation Versus Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Nimotuzumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms NICE
  • Sponsors Eurofarma
  • Most Recent Events

    • 24 Nov 2017 Results assessing safety and efficacy of chemoradiation combined with nimotuzumab, published in the European Journal of Cancer.
    • 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 17 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov. record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top